Cipla Ltd.’s planned acquisition of InvaGen Inc. and Exelan Pharmaceuticals is the second such buyout deal involving an Indian firm in the US, after Lupin snapped up the privately owned niche firm Gavis Pharmaceuticals LLC and Novel Laboratories Inc. for $880m in July.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?